Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.29
-0.14 (-2.18%)
At close: Apr 28, 2026, 4:00 PM EDT
6.29
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:29 PM EDT
Aligos Therapeutics Employees
Aligos Therapeutics had 82 employees as of December 31, 2025. The number of employees increased by 12 or 17.14% compared to the previous year.
Employees
82
Change (1Y)
12
Growth (1Y)
17.14%
Revenue / Employee
$26,659
Profits / Employee
-$295,037
Market Cap
38.92M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| Werewolf Therapeutics | 39 |
| Actinium Pharmaceuticals | 25 |
| INmune Bio | 21 |
| Veru Inc. | 20 |
| RenovoRx | 17 |
| Sensei Biotherapeutics | 15 |
| CervoMed | 15 |
ALGS News
- 4 days ago - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates - Benzinga
- 12 days ago - Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - GlobeNewsWire
- 14 days ago - Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation - GlobeNewsWire
- 7 weeks ago - Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) - GlobeNewsWire
- 3 months ago - Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - GlobeNewsWire